Novo Nordisk Launches Self-Pay Weight-Loss Pill

Novo Nordisks weight-loss pill, Wegovy, gains FDA approval, marking a new strategy for the Danish drugmaker. Launching directly to cash-paying customers in the U.S., Novo aims to bypass insurance wait times. The oral treatment, priced at $149 per month, will be available at retail spots, online, and through telehealth partners. This move comes as Novo competes with Eli Lillys Zepbound and cheaper alternatives, seeking to reclaim market value lost due to competition. Experts predict oral drugs like Wegovy could capture 20% of the global obesity market by 2030, potentially reshaping how blockbuster drugs reach consumers.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.